Physiological study of Aurora kinase A (AURKA) in relation with Breast Cancer Tissue
DOI:
https://doi.org/10.36320/ajb/v18.i1.23024Keywords:
Breast cancer; Aurora kinase A (AURKA)Abstract
Abstract
Background: Breast cancer, a widespread and frequently fatal condition impacting women globally, results in over 40,000 deaths each year. The disease presents in multiple forms, such as benign tumors, normal tissue, in situ carcinoma, and invasive carcinoma. Despite advancements in early identification and treatment efficacy, 20% to 30% of women diagnosed with breast cancer develop metastatic illness, often affecting visceral organs, either at the time of diagnosis or as the disease progresses.
Aims: The aim of this study is to Investigate the expression levels of the biochemical marker AURKA and its function in tumor proliferation.
Methods: A total of 60 females diagnosed with breast cancer were selected from Al-WATANI Oncology Hospital and Center Labs in Najaf for further laboratory research. Additionally, 30 females, free from any known diseases and apparently healthy, were recruited as control subjects.
Results: The findings indicate that the patient group demonstrates a higher average value (3.3 ± 1.0) in comparison to the control group (1.6 ± 0.15), reflecting a raw difference of roughly (1.7). Statistical testing reveals no significant difference between the two groups, as indicated by a p-value of 0.095.
Conclusion: The data reveals no substantial increase in the biochemical marker AURKA, as shown by the results. This marker may still be significant in breast cancer progression, likely due to its role in cell cycle regulation and tumor development.
Downloads
References
References
1.Kaddes, M., Ayid, Y. M., Elshewey, A. M., & Fouad, Y. (2025). Breast cancer classification based on hybrid CNN with LSTM model. Scientific Reports, 15(1), 4409.
2. Trayes, K. P., & Cokenakes, S. E. (2021). Breast cancer treatment. American family physician, 104(2), 171-178.
3. Delaloge, S., Khan, S. A., Wesseling, J. & Whelan, T. Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment. Lancet 403, 2734–2746 (2024)
4.Xiong, X., Zheng, L. W., Ding, Y., Chen, Y. F., Cai, Y. W., Wang, L. P., ... & Yu, K. D. (2025). Breast cancer: pathogenesis and treatments. Signal transduction and targeted therapy, 10(1), 49.
5. Ingebriktsen, L. M., Humlevik, R. O. C., Svanøe, A. A., Sæle, A. K. M., Winge, I., Toska, K., ... & Wik, E. (2024). Elevated expression of Aurora-A/AURKA in breast cancer is associated with younger age and aggressive features. Breast Cancer Research, 26(1), 126.
6. Wang, F., Zhang, H., Wang, H., Qiu, T., He, B., & Yang, Q. (2022). Combination of AURKA inhibitor and HSP90 inhibitor to treat breast cancer with AURKA overexpression and TP53 mutations. Medical Oncology, 39(12), 180.
7. Li J, Gong C, Zhou H, Liu J, Xia X, Ha W, et al. Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives. Int J Mol Sci. 2024; 25:5489.
8. Whately, K. M., Voronkova, M. A., Maskey, A., Gandhi, J., Loskutov, J., Choi, H., ... & Pugacheva, E. N. (2021). Nuclear Aurora-A kinase-induced hypoxia signaling drives early dissemination and metastasis in breast cancer: implications for detection of metastatic tumors. Oncogene, 40(37), 5651-5664.
9. Du R, Huang C, Liu K, Li X, Dong Z. Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy. Mol Cancer. 2021;20(1):15.
10.Goos, J. A., Coupe, V. M., Diosdado, B., Delis-van Diemen, P. M., Karga, C., Beliën, J. A., ... & Fijneman, R. J. (2013). Aurora kinase A (AURKA) expression in colorectal cancer liver metastasis is associated with poor prognosis. British journal of cancer, 109(9), 2445-2452.
11. Kotowicz, B., Winter, P., Fuksiewicz, M., Jagiello-Gruszfeld, A. I., Pogoda, K., Nowecki, Z., & Kowalska, M. (2020). Clinical value of kinase Aurora-A serum level determination in patients with breast cancer qualified for neoadjuvant chemotherapy: Pilot study.
12. Goh, L. P. W., See, E. U. H., Chua, K. H., & Lee, P. C. (2018). Reduced
expression of AURKA in peripheral blood of breast cancer patients. BioTechnologia.
Journal of Biotechnology Computational Biology and Bionanotechnology, 99(1).
13.Moelans, C. B., de Wegers, R. A., Monsuurs, H. N., Maess, A. H., & Van Diest, P. J. (2011). Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study. Cellular Oncology, 34(5), 475-482.
14. Ingebriktsen, L. M., Humlevik, R. O. C., Svanøe, A. A., Sæle, A. K. M., Winge, I., Toska, K., ... & Wik, E. (2024). Elevated expression of Aurora-A/AURKA in breast cancer is associated with younger age and aggressive features. Breast Cancer Research, 26(1), 126.
15.Fadaka, A. O., Sibuyi, N. R. S., Madiehe, A. M., & Meyer, M. (2020). MicroRNA-based regulation of Aurora A kinase in breast cancer. Oncotarget, 11(46), 4306
16. Siggelkow, W., Boehm, D., Gebhard, S., Battista, M., Sicking, I., Lebrecht, A., ... & Schmidt, M. (2012). Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients. BMC cancer,
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Shahad Merza, Adhraa Baqer Hassan
This work is licensed under a Creative Commons Attribution 4.0 International License.
which allows users to copy, create extracts, abstracts, and new works from the Article, alter and revise the Article, and make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work.
